

Author: Farkad Ezzet David Wexler Rachel Courtney Gopal Krishna Josephine Lim Mark Laughlin
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.44, Iss.2, 2005-01, pp. : 211-220
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. :


Bioavailability of valsartan oral dosage forms
Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. :


By Pokrajac M. Miljkovic B. Simic D. Brzakovic B. Galetin A.
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 43, Iss. 2, 1997-04 ,pp. :


By Staab A. Schug B.S. Larsimont V. Elze M. Thummler D. Mutschler E. Blume H.
European Journal of Pharmaceutical Sciences, Vol. 18, Iss. 2, 2003-02 ,pp. :